DDW’s Megan Thomas talks to Ali Tavassoli, Chief Scientific Officer of Curve Therapeutics and Professor of Chemical Biology at the University of Southampton, UK. MT: Where do you work, and can you tell us what you’re working on at the moment? AT: We spun Curve out of my academic… Read More
Curve Therapeutics’ CSO Ali Tavassoli has published an article in the Journal of the American Chemical Society (JACS) which highlights the potential of HIF inhibition as a therapeutic approach for cancers. The paper is titled ‘Identification and Development of Cyclic Peptide Inhibitors of Hypoxia Inducible Factors (HIF) 1 and… Read More
Curve Therapeutics, a company developing an intracellular screening platform to address disease targets, has completed a £40.5 million ($51.37 million) Series A financing round. Pfizer Ventures led the round with participation from Columbus Venture Partners and British Patient Capital, which join founding investor Advent Life Sciences and… Read More
